Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Evaluation of Pembrolizumab in Combination With Anlotinib in the Treatment of Refractory or Recurrent High-Grade Serous Ovarian Cancer

NCT05188781 is registered in ClinicalTrials.gov with The Affiliated Hospital of Qingdao University as lead sponsor.

NCT NCT05188781
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05188781 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Evaluation of Pembrolizumab in Combination With Anlotinib in the Treatment of Refractory or Recurrent High-Grade Serous Ovarian Cancer
Lead sponsor
The Affiliated Hospital of Qingdao University
Phase
Observational
Overall status
Completed
Start date
January 4, 2019
Completion date
August 23, 2021
Enrollment
34 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

high-grade serous ovarian cancer